4 December 2018 - Between 2000 and 2016, no new drugs were approved for cancers of the brain, and there were only a handful for liver, ovarian and pancreatic cancers.

 Cancer is a moving target. Its ability to adapt to treatment and develop resistance is the single biggest challenge in the field and the reason why the disease claims so many lives. 

We need a diverse toolbox of innovative drugs that attack cancer in new ways and get ahead of its evolution.

Read Financial Times article